CTLA4 and myeloid sarcoma: History of MS was confirmed in 8 (57%) cases, the median time to the beginning of symptoms was 29 days, two patients died because of their relapse, and there was no difference in outcomes between CTLA-4 and PD-1/PD-L1 inhibitors.